Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

DOTA-Tyr(1)-octreotate

Known as: DOTA-1-Tyr-octreotate, DOTA-1-tyrosyl-octreotate, DOTA-Y1-TATE 
National Institutes of Health

Related topics

Related topics

4 relations

Narrower (1)

DOTA-D-Tyr(1)-octreotate

Broader (2)

Heterocyclic Compounds, 1-RingOctreotide
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
NeuroEndocrine Tumor Therapy with Lutetium-177-octreotate and Everolimus (NETTLE): A Phase I Study
Abstract Objective: To establish the optimal safe dose of everolimus in combination with 177Lu-octreotate peptide receptor… Expand
2015
2015
NeuroEndocrine Tumor Therapy with Lutetium-177-octreotate and Everolimus (NETTLE): A Phase I Study.
OBJECTIVE To establish the optimal safe dose of everolimus in combination with (177)Lu-octreotate peptide receptor radionuclide… Expand
Highly Cited
2014
Highly Cited
2014
Preclinical Evaluation of a High-Affinity 18F-Trifluoroborate Octreotate Derivative for Somatostatin Receptor Imaging
Recent studies have highlighted the high sensitivity of PET imaging with 68Ga-labeled octreotide derivatives for the detection… Expand
  • figure 1
  • figure 3
  • figure 4
  • figure 6
  • figure 5
2014
2014
Hematological Toxicity of Combined 177Lu-Octreotate Radiopeptide Chemotherapy of Gastroenteropancreatic Neuroendocrine Tumors in Long-Term Follow-Up
Background: The combination of radiopeptide therapy [peptide receptor radionuclide therapy (PRRT)] with radiosensitizing… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
Review
2014
Review
2014
Peptide receptor radionuclide therapy for advanced neuroendocrine tumors.
Peptide receptor radionuclide therapy (PRRT) consists of the systemic administration of a synthetic peptide, labeled with a… Expand
2011
2011
Response and Long-Term Control of Bone Metastases After Peptide Receptor Radionuclide Therapy with 177Lu-Octreotate
Peptide receptor radionuclide therapy (PRRT) is an efficient treatment for gastroenteropancreatic neuroendocrine tumors (GEP NETs… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Review
2010
Review
2010
Use of molecular targeted agents for the diagnosis, staging and therapy of neuroendocrine malignancy
  • R. Hicks
  • Cancer imaging : the official publication of the…
  • 2010
    • Corpus ID: 16242870
Abstract Imaging of neuroendocrine tumours (NET) poses significant challenges because of the heterogeneous biology of the tumours… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Review
2010
Review
2010
Therapies for the medical management of persistent hypoglycaemia in two cases of inoperable malignant insulinoma.
OBJECTIVE Hypoglycaemia poses a significant management challenge in patients with unresectable functional malignant insulinoma… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Highly Cited
2001
Highly Cited
2001
Receptor-targeted optical imaging of tumors with near-infrared fluorescent ligands
We report here the in vivo diagnostic use of a peptide–dye conjugate consisting of a cyanine dye and the somatostatin analog… Expand
  • figure 3
  • figure 2
  • figure 5
  • figure 4
  • figure 6
Highly Cited
2001
Highly Cited
2001
[177Lu‐DOTA0,Tyr3]octreotate for somatostatin receptor‐targeted radionuclide therapy
Receptor‐targeted scintigraphy using radiolabeled somatostatin analogs such as octreotate is being used with great success to… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE